News

ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Research Capabilities in Infectious, Immunologic, and Allergic Diseases

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). With this contract, ATCC will support NIAID’s Division of Clinical Research, Division of Intramural Research, and Vaccine Research Center with rapid response capabilities to infectious disease issues, such as COVID-19, as well as provide quality services across basic science, preclinical, clinical, assay development, and vaccine production.

The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH)’s mission is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID advances the understanding, diagnosis, and treatment of many of the world’s most intractable and widespread diseases. In 2017, NIAID drafted guidelines for “Emerging Infectious Disease Outbreak Research Response” based on lessons learned during outbreaks, such as Zika and Ebola. The most recent COVID‐19 outbreak further demonstrated the immediate need for more efficient reaction times and mechanisms to improve response and quality services.

“ATCC’s scientific, supply and cold chain logistics, and repository expertise in global health priorities will provide NIAID with rapid response capabilities to infectious disease issues to help save lives and ensure the protection of people worldwide,” said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. “With our biorepository services, including an FDA-registered facility for worldwide storage and distribution of biological materials, we are well-positioned to support NIAID with its pandemic preparedness and response.”

Specifically, ATCC’s role will involve the following activities: storage and repository; quality management; facilities, equipment and resource support/operations; supply chain and logistics management; and technical reporting. For decades, ATCC has supported government agencies with curated, high-quality biomaterials and resources, laboratory services, and repository operations.

“With this award, ATCC continues its development of a large new contract vehicle in the government sector leveraging expertise in infectious disease research and development,” said Joseph Leonelli, Ph.D., senior vice president of ATCC Federal Solutions. “We look forward to collaborating with NIAID to provide them with the solutions they need to advance global health.”

Recent News

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them